0R02 Stock Overview
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Organovo Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.27 |
| 52 Week High | US$2.04 |
| 52 Week Low | US$0.96 |
| Beta | 0.90 |
| 1 Month Change | 24.51% |
| 3 Month Change | 23.52% |
| 1 Year Change | -42.01% |
| 3 Year Change | -86.46% |
| 5 Year Change | -93.77% |
| Change since IPO | -99.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R02 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0.6% | -1.9% | -0.9% |
| 1Y | -42.0% | -30.5% | -1.8% |
Return vs Industry: 0R02 underperformed the UK Biotechs industry which returned -30.5% over the past year.
Return vs Market: 0R02 underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| 0R02 volatility | |
|---|---|
| 0R02 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0R02 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0R02's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 18 | n/a | www.organovo.com |
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments.
Organovo Holdings, Inc. Fundamentals Summary
| 0R02 fundamental statistics | |
|---|---|
| Market cap | US$11.04m |
| Earnings (TTM) | -US$19.08m |
| Revenue (TTM) | US$242.00k |
45.6x
P/S Ratio-0.6x
P/E RatioIs 0R02 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R02 income statement (TTM) | |
|---|---|
| Revenue | US$242.00k |
| Cost of Revenue | US$8.89m |
| Gross Profit | -US$8.64m |
| Other Expenses | US$10.44m |
| Earnings | -US$19.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.90 |
| Gross Margin | -3,571.49% |
| Net Profit Margin | -7,886.36% |
| Debt/Equity Ratio | 0% |
How did 0R02 perform over the long term?
See historical performance and comparison